- Home
- SKIN vs CVRX Comparison
SKIN vs CVRX Comparison
Compare SKIN & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | CVRX |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 179.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKIN | CVRX |
|---|---|---|
| Price | $1.29 | $6.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.00 | ★ $11.40 |
| AVG Volume (30 Days) | ★ 446.4K | 402.7K |
| Earning Date | 03-11-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $301,917,000.00 | $55,969,000.00 |
| Revenue This Year | N/A | $11.91 |
| Revenue Next Year | $4.42 | $15.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.44 |
| 52 Week Low | $0.78 | $4.30 |
| 52 Week High | $2.69 | $16.59 |
Technical Indicators
Market Signals| Indicator | SKIN | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 45.09 |
| Support Level | $1.39 | $6.36 |
| Resistance Level | $1.55 | $7.42 |
| Average True Range (ATR) | 0.07 | 0.69 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 0.50 | 59.52 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.